Document Type : Original Article
Authors
1 Student Research Committee, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Psychiatric Nursing and Management, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Department of Psychiatric Nursing and Management, School of Nursing and Midwifery,, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Basic Sciences, School of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract
Background: Cancer as a chronic and severe disease, causes a lot of psychological distress in patients. One of the psychological interventions to control distress is metacognitive therapy. The aim of this study was to evaluate this type of treatment on life expectancy and consequently adherence to the treatment of the patients.
Methods: This study was a quasi-experimental two-group study. A total of 70 patients with gestational cancer were selected by convenience sampling and randomly divided into the intervention (n = 35) and control (n = 35) groups. The intervention group received 5 sessions (45-60 min) of metacognitive therapy, but the control group received the routine intervention. Data were collected using three questionnaires including: demographic and disease data questionnaire, Madanloo Treatment Adherence Questionnaire and Snyder’s Hope Scale.
Results: Metacognitive therapy made significant changes in life expectancy and adherence to treatment in the intervention group compared to the control group (P < 0.0001). The results of an adjusted analysis of covariance to compare the scores of treatment adherence and life expectancy after the intervention in the intervention group were 15.55 and 19.6 higher on average, respectively.
Conclusion: The study indicates that metacognitive therapy has been effective in improving life expectancy and adherence to treatment of patients with gastrointestinal cancer. This intervention can be considered as an effective psychological intervention for these patients. Therefore, it is suggested that this intervention be established and promoted in counseling and psychotherapy centers in hospitals and treatment centers to accelerate the recovery process of these patients.
Keywords
treatment guidelines 2018 (5th edition). Gastric Cancer.
2021;24(1):1-21. doi: 10.1007/s10120-020-01042-y.
2. Jameson JL, Kasper DL, Fauci AS, Hauser SL, Longo DL,
Loscalzo J. Harrison’s Principles of Internal Medicine. 20th
ed. McGraw Hill; 2018.
3. He XX, Yuan SY, Li WB, Yang H, Ji W, Wang ZQ, et al.
Improvement of Asia-Pacific colorectal screening score and
evaluation of its use combined with fecal immunochemical
test. BMC Gastroenterol. 2019;19(1):226. doi: 10.1186/
s12876-019-1146-2.
4. Quattropani MC, Lenzo V, Mucciardi M, Toffle ME. The role of
metacognitions in predicting anxiety and depression levels in
cancer patients ongoing chemotherapy. Procedia Soc Behav
Sci. 2015;205:463-73. doi: 10.1016/j.sbspro.2015.09.042.
5. Kavosi A, Moeini Ghamchini V, Baiky F, Khalili G,
Mohammadi G, Baiky F, et al. The relationship between
metacognitive beliefs with quality of life and mental health
of patients with cancer: a case-control study. Iran J Nurs Res.
2017;12(1):35-41. doi: 10.21859/ijnr-12016. [Persian ].
6. Bush ML, Kaufman MR, Shackleford T. Adherence in the
cancer care setting: a systematic review of patient navigation
to traverse barriers. J Cancer Educ. 2018;33(6):1222-9. doi:
10.1007/s13187-017-1235-2.
7. Cheville AL, Alberts SR, Rummans TA, Basford JR, Lapid
Journal of Kerman University of Medical Sciences. Volume 29, Number 5, 2022 483
The Effect of Metacognitive Therapy on …
MI, Sloan JA, et al. Improving adherence to cancer
treatment by addressing quality of life in patients with
advanced gastrointestinal cancers. J Pain Symptom Manage.
2015;50(3):321-7. doi: 10.1016/j.jpainsymman.2015.03.005.
8. Hall AE, Paul C, Bryant J, Lynagh MC, Rowlings P, Enjeti
A, et al. To adhere or not to adhere: Rates and reasons of
medication adherence in hematological cancer patients.
Crit Rev Oncol Hematol. 2016;97:247-62. doi: 10.1016/j.
critrevonc.2015.08.025.
9. Ok E, Kutlu FY. Hopelessness, anxiety, depression and
treatment adherence in chronic hemodialysis patients. Int J
Caring Sci. 2019;12(1):423-9.
10. Derakhshani M, Seief AA. The effectiveness of group hope
therapy on the time horizon and optimism. Interdiscip J Educ.
2016;1(1):7-18.
11. Wiggins DL, Monzon C, Hott BR. The impact of reproductive
cancers on women’s mental health. In: Barnes DL, ed.
Women’s Reproductive Mental Health Across the Lifespan.
Cham: Springer; 2014. p. 283-300. doi: 10.1007/978-3-319-
05116-1_15.
12. Alagheband M, Servat F, Zarepour F. Investigation of the
relationship between quality of life and life expectancy in
patients with breast cancer. Tolooebehdasht. 2016;15(2):175-
85. [Persian].
13. Purushotham A, Bains S, Lewison G, Szmukler G, Sullivan
R. Cancer and mental health--a clinical and research unmet
need. Ann Oncol. 2013;24(9):2274-8. doi: 10.1093/annonc/
mdt214.
14. Madani H, Pourmemari M, Moghimi M, Rashvand F.
Hopelessness, perceived social support and their relationship
in Iranian patients with cancer. Asia Pac J Oncol Nurs.
2018;5(3):314-9. doi: 10.4103/apjon.apjon_5_18.
15. Movahedi M, Movahedi Y, Farhadi A. Effect of hope therapy
training on life expectancy and general health in cancer
patients. J Holist Nurs Midwifery. 2015;25(2):84-92. [Persian].
16. Fisher PL, Byrne A, Fairburn L, Ullmer H, Abbey G, Salmon
P. Brief metacognitive therapy for emotional distress in adult
cancer survivors. Front Psychol. 2019;10:162. doi: 10.3389/
fpsyg.2019.00162.
17. Thewes B, Bell ML, Butow P. Fear of cancer recurrence in young
early-stage breast cancer survivors: the role of metacognitive
style and disease-related factors. Psychooncology.
2013;22(9):2059-63. doi: 10.1002/pon.3252.
18. Asaszadeh I, Mahmoudalilou M. The study of the effectiveness
of metacognitive therapy on depressive symptoms and life
expectancy of women with breast cancer. Clin Psychol Stud.
2018;8(29):69-95. doi: 10.22054/jcps.2018.8315. [Persian].
19. Kahrazei F, Danesh E, Hydarzadegan A. The effect of cognitivebehavioral
therapy (CBT) on reduction of psychological
symptoms among patients with cancer. Zahedan J Res Med
Sci. 2012;14(2):112-6. [Persian].
20. Esbjørn BH, Normann N, Christiansen BM, Reinholdt-
Dunne ML. The efficacy of group metacognitive therapy
for children (MCT-c) with generalized anxiety disorder: An
open trial. J Anxiety Disord. 2018;53:16-21. doi: 10.1016/j.
janxdis.2017.11.002.
21. Nordahl HM, Borkovec TD, Hagen R, Kennair LEO, Hjemdal
O, Solem S, et al. Metacognitive therapy versus cognitivebehavioural
therapy in adults with generalised anxiety
disorder. BJPsych Open. 2018;4(5):393-400. doi: 10.1192/
bjo.2018.54.
22. Strand ER, Hagen R, Hjemdal O, Kennair LEO, Solem S.
Metacognitive therapy for depression reduces interpersonal
problems: results from a randomized controlled trial. Front
Psychol. 2018;9:1415. doi: 10.3389/fpsyg.2018.01415.
23. Ng DWL, Kwong A, Suen D, Chan M, Or A, Ng SS, et al.
Fear of cancer recurrence among Chinese cancer survivors:
prevalence and associations with metacognition and
neuroticism. Psychooncology. 2019;28(6):1243-51. doi:
10.1002/pon.5073.
24. Wells A, Walton D, Lovell K, Proctor D. Metacognitive
therapy versus prolonged exposure in adults with chronic
post-traumatic stress disorder: a parallel randomized
controlled trial. Cognit Ther Res. 2015;39(1):70-80. doi:
10.1007/s10608-014-9636-6.
25. Wells A. Metacognitive Therapy for Anxiety and Depression.
Guilford Press; 2011.
26. Seyed Fatemi N, Rafii F, Hajizadeh E, Modanloo M.
Psychometric properties of the adherence questionnaire in
patients with chronic disease: a mix method study. Koomesh.
2018;20(2):179-91. [Persian].
27. Kermani Z, Khodapanahi MK, Heidari M. Psychometrics
features of the Snyder Hope Scale. J Appl Psychol. 2011;5(3):7-
23. [Persian].
28. Winter L, Schweiger U, Kahl KG. Feasibility and outcome
of metacognitive therapy for major depressive disorder: a
pilot study. BMC Psychiatry. 2020;20(1):566. doi: 10.1186/
s12888-020-02976-4.
29. Miegel F, Demiralay C, Moritz S, Wirtz J, Hottenrott B,
Jelinek L. Metacognitive training for obsessive-compulsive
disorder: a study protocol for a randomized controlled trial.
BMC Psychiatry. 2020;20(1):350. doi: 10.1186/s12888-020-
02648-3.
30. Farshidfar Z, Rahimian-Booger I, Asadi J, Izadpanahi P. The
effectiveness of group-based behavioral activation therapy on
adherence to treatment of women with breast cancer. Feyz.
2019;23(5):511-20. [Persian].
31. Wells A, Fisher P, Myers S, Wheatley J, Patel T, Brewin CR.
Metacognitive therapy in treatment-resistant depression:
a platform trial. Behav Res Ther. 2012;50(6):367-73. doi:
10.1016/j.brat.2012.02.004.
32. Lakshmi J, Sudhir PM, Sharma MP, Math SB. Effectiveness of
metacognitive therapy in patients with social anxiety disorder:
a pilot investigation. Indian J Psychol Med. 2016;38(5):466-
71. doi: 10.4103/0253-7176.191385.
33. Mousavizadeh SN, Banazadeh Z. Loss of time in the treatment
adherence process: a qualitative study in a sample of
Iranian people with diabetes. Journal of Medicine and Life.
2020;13(3):293-299. doi: 10.25122/jml-2019-0110. [Persian]
34. Khait AA, Lazenby M. Psychotherapeutic Interventions
Among Muslims Undergoing Treatment for Cancer: An
Integrative Review. Research Square. 2020:1-14.
35. Moghadamfar N, Amraei R, Asadi F, Amani O. The efficacy
of acceptance and commitment therapy (ACT) on hope
and psychological well-being in women with breast cancer
under chemotherapy. Iranian Journal of Psychiatric Nursing.
2018;6(5):1-7. doi: 10.21859/ijpn-06051. [Persian].
36. Bagheri Zanjani Asl Monfared L, Entesar Foumany G. The
effectiveness of group based hope- therapy on increasing
resilience and hope in life expectancy in patients with
breast cancer. Journal of Health Promotion Management.
2016;5(4):58-64. [Persian].
37. Lopez-Morinigo JD, Ajnakina O, Martínez AS, Escobedo-
Aedo PJ, Ruiz-Ruano VG, Sánchez-Alonso S, et al. Can
metacognitive interventions improve insight in schizophrenia
spectrum disorders? A systematic review and meta-analysis.
Psychol Med. 2020;50(14):2289-301. doi: 10.1017/
s0033291720003384.
)